PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2020

Narciclasine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress.

Rat / Endotoxin/LPS

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 32693689 ↗2020Reported benefit

Narciclasine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress.

RatEndotoxin/LPSSprague-Dawleymalen = 75 neonatal rats in total, 15 per group across five groupsintraperitoneal in the LPS plus narciclasine group; subcutaneous injection into the neck is described for the narciclasine-only group0.7 mg/kg in 200 microlitres12 h prior to LPS exposure

Model: Lipopolysaccharide-induced neonatal acute lung injury (LPS 2 mg/kg intraperitoneally)

Narciclasine reduced histological lung injury and pulmonary oedema, lowered serum cytokines and lung adhesion molecules, decreased ROS, LDH and MPO while increasing SOD, reduced apoptosis, and suppressed TLR4/NF-kappaB/Cox2 pathway activation.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.